NIKKEI 225
28,249.24 +73.37 (+0.26%) HANG SENG
20,045.77 -156.17 (-0.77%) CRUDE OIL
90.26 +1.25 (+1.40%) GOLD FUTURES
1,804.20 +13.00 (+0.73%) DOW
32,838.41 +34.94 (+0.11%) BTC-GBP
19,712.89 +440.31 (+2.28%)
Biocartis Group NV (BCART.BR)
| Previous close | 1.7180 |
| Open | 1.7300 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's range | 1.6900 - 1.7300 |
| 52-week range | 1.6660 - 4.3800 |
| Volume | |
| Avg. volume | 57,688 |
| Market cap | 98.173M |
| Beta (5Y monthly) | 1.60 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.2040 |
| Earnings date | 23 Feb 2022 - 28 Feb 2022 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 4.50 |
- Globe Newswire
Press release Biocartis Group NV: Biocartis Announces New Agreement with AstraZeneca for the Development and Marketing of a Companion Diagnostic Test for Tagrisso®
PRESS RELEASE: 22 June 2022, 07:00 CEST Biocartis Announces New Agreement with AstraZeneca for the Development and Marketing of a Companion Diagnostic Test for Tagrisso® Mechelen, Belgium, 22 June 2022 – Biocartis Group NV (the ‘Company’ or ‘Biocartis’), an innovative molecular diagnostics company (Euronext Brussels: BCART), today announced that it has entered into an agreement with AstraZeneca (LSE/STO/Nasdaq: AZN) aimed at the development and applicable pre-market notification or approval with
- Globe Newswire
Press release Biocartis Group NV: Biocartis Announces Launch of its Rapid CE-marked IVD Idylla™ GeneFusion Panel for Fast Treatment Decisions in Lung Cancer
PRESS RELEASE: 20 June 2022, 07:00 CEST Biocartis Announces Launch of its Rapid CE-marked IVD Idylla™ GeneFusion Panel for Fast Treatment Decisions in Lung Cancer Idylla™ GeneFusion Panel available as rapid CE-marked IVD lung cancer testing solution for laboratories, with results within 180 minutes10% to 20% of advanced lung cancer patients don’t receive the appropriate targeted therapy due to slow turnaround time of many current testing methods, leading to a delayed time-to-treatment1 Mechelen,
- Globe Newswire
Press release Biocartis Group NV: Biocartis Reaches Key Commercial Milestones: One-Millionth Idylla™ Cartridge Sold and 2,000th Idylla™ Instrument Placed
PRESS RELEASE: 15 June 2022, 07:00 CEST Biocartis Reaches Key Commercial Milestones: One-Millionth Idylla™ Cartridge Sold and 2,000th Idylla™ Instrument Placed Mechelen, Belgium, 15 June 2022 – Biocartis Group NV (the ‘Company’ or ‘Biocartis’), an innovative molecular diagnostics company (Euronext Brussels: BCART), announces a double milestone today: the selling of its one-millionth commercial Idylla™ cartridge and the placement of its 2,000th Idylla™ instrument since its commercial launch. Thes
